Athira Pharma, Inc. Common Stock (ATHA) is a publicly traded Healthcare sector company. As of May 21, 2026, ATHA trades at $6.75 with a market cap of $26.62M and a P/E ratio of -0.27. ATHA moved -7.53% today. Year to date, ATHA is +1566.67%; over the trailing twelve months it is +1042.91%. Its 52-week range spans $0.22 to $8.36. Analyst consensus is hold with an average price target of $13.33. Rallies surfaces ATHA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
ATHA Energy Secures US$20M Convertible Debenture Financing at 12% Coupon: ATHA Energy secured US$20 million in 5-year convertible debentures from Queen’s Road Capital, featuring a 12% coupon and C$0.85 conversion price per share. Proceeds will fund exploration across its 7 million-acre Canadian uranium portfolio, including advancing post-discovery drilling at the Angilak project and high-grade GMZ target.
| Metric | Value |
|---|---|
| Price | $6.75 |
| Market Cap | $26.62M |
| P/E Ratio | -0.27 |
| EPS | $-24.70 |
| Dividend Yield | 0.00% |
| 52-Week High | $8.36 |
| 52-Week Low | $0.22 |
| Volume | 70.26K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-105.61M |
| Gross Margin | 0.00% |
5 analysts cover ATHA: 0 strong buy, 0 buy, 5 hold, 0 sell, 0 strong sell. Consensus rating is hold. Average price target: $13.33.